RICHTER, S.; SEAH, J.-A.; POND, G. R.; GAN, H. K.; MACKENZIE, M. J.; HOTTE, S. J.; MUKHERJEE, S. D.; MURRAY, N.; KOLLMANNSBERGER, C.; HENG, D.; HAIDER, M. A.; HALFORD, R.; IVY, S. P.; MOORE, M. J.; SRIDHAR, S. S. Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib. Canadian Urological Association Journal, [S. l.], v. 8, n. 11-12, p. 398–402, 2014. DOI: 10.5489/cuaj.2426. Disponível em: https://cuaj.ca/index.php/journal/article/view/2426. Acesso em: 6 may. 2024.